Although progress has been made in the treatment of pancreatic cancer, further research is required to identify novel therapeutic options to improve the outlook of patients with this cancer. In addition, quality of life must be considered when selecting the optimal treatment. In this interview Derek Grose, MBChB, MRCP, FRCR, MD of the Beatson West of Scotland Cancer Centre, Glasgow, UK discusses the current treatment landscape for pancreatic cancer and progression that has been made in this area, including the transition from single agent to triplet chemotherapy, and the advent of second line therapy trials. He also discusses quality vs. quantity of life regarding novel drugs for pancreatic cancer treatment. This interview was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.